This was also reflected in patient survival, as anti-PD-1-treated patients with melanoma and ELOVL1low TILs showed better overall survival than anti-PD-1-treated patients with melanoma and ELOVL1high TILs, albeit borderline significantly (Extended Data Fig. 2e). Here, PDCD1 is linked to melanoma.